| Cell line name |
Me1386 |
|---|
| Synonyms |
Me 1386 |
|---|
| Accession |
CVCL_VU55 |
|---|
| Resource Identification Initiative |
To cite this cell line use: Me1386 (RRID:CVCL_VU55) |
|---|
| Comments |
Derived from site: Metastatic; Not specified. |
|---|
| Sequence variations |
- Mutation; HGNC; HGNC:914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Homozygous (PubMed=9637706).
|
|---|
| HLA typing |
Source: PubMed=9637706
| Class I | | HLA-A | A*01,31 | | HLA-B | B*08,51 | | HLA-C | C*w07 |
|
|---|
| Disease |
Melanoma (NCIt: C3224) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Sex of cell |
Sex unspecified |
|---|
| Age at sampling |
Age unspecified |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=9637706; DOI=10.1172/JCI498; PMCID=PMC508863
Daniel J. Hicklin, Zhi-Gang Wang, Flavio Arienti, Licia Rivoltini, Giorgio Parmiani, Soldano Ferrone;
Beta2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
J. Clin. Invest. 101:2720-2729(1998) |
|---|
| Cross-references |
|---|
| Encyclopedic resources |
Wikidata; Q95987967
|
|---|
| Polymorphism and mutation databases |
Cosmic; 2759877
|
|---|
| Entry history |
|---|
| Entry creation | 24-May-2019 |
|---|
| Last entry update | 14-Aug-2025 |
|---|
| Version number | 7 |
|---|
